White Paper 'Computer Aided Auscultation of the Heart, the Clinical Opportunity' Available at Zargis Website
November 29 2004 - 8:41AM
PR Newswire (US)
White Paper 'Computer Aided Auscultation of the Heart, the Clinical
Opportunity' Available at Zargis Website PRINCETON, N.J., Nov. 29
/PRNewswire-FirstCall/ -- Zargis Medical Corp., a majority-owned
subsidiary of Speedus Corp. (NASDAQ:SPDE), announced today it has
released a white paper that summarizes the state of the art in
cardiac auscultation, reviews the clinical challenges and
opportunities, and evaluates the use of echocardiography in the
assessment of patients with heart murmurs. The paper also describes
computer aided auscultation in detail and assesses the clinical
utility of such a system. This white paper was commissioned by
Zargis and written by Apothecom Associates, LLC located in Yardley,
PA and can be accessed by visiting the Zargis website at
http://www.zargis.com/ or by sending an email request to .
"Apothecom has done an excellent job of consolidating and
commenting on more than 70 published research articles in the area
of auscultation. After reading this white paper, one understands
the merits of Zargis' research and development efforts as well as
our value proposition to clinicians and to the healthcare system in
general." commented John Kallassy, the Managing Director of Zargis
Medical. About Zargis Medical Corp. Zargis Medical Corp. was formed
in January 2001 when Siemens Corporate Research Inc., a subsidiary
of Siemens AG (NYSE:SI), and Speedus Corp. (NASDAQ:SPDE)
co-invested in Zargis to further develop and commercially market an
advanced acoustic technology for detecting abnormalities identified
through analysis of heart sounds. Based in Princeton, New Jersey,
Zargis is developing advanced diagnostic decision support products
and services for primary care physicians, pediatricians,
cardiologists and other healthcare professionals. Zargis has
developed Cardioscan, the first and only FDA approved computer-
assisted medical device to support physicians in analyzing heart
sounds for the identification of suspected murmurs, a potential
sign of heart disease. Cardioscan is easy to use, non-invasive,
portable, and takes just minutes to perform. Developed by
scientists from Siemens and Zargis over many years, Cardioscan
implements voice-guided protocol and graphical user interface while
maintaining an efficient physician workflow. The system provides a
summary of findings in terms that are readily understood by
physicians with more quantitative auscultatory information than is
possible through listening alone. Thus, Cardioscan enhances
auscultation which has been universally employed through a
stethoscope for nearly two hundred years. For additional
information on Speedus Corp. or Zargis Medical, contact John
Kallassy, 718.567.4358, , or visit their websites at
http://www.speedus.com/ and http://www.zargis.com/. For additional
information on Siemens Corporate Research, visit their website at
http://www.scr.siemens.com/. Statements contained herein that are
not historical facts, including but not limited to statements about
the Company's product, corporate identity and focus, may be
forward-looking statements that are subject to a variety of risks
and uncertainties. There are a number of important factors that
could cause actual results to differ materially from those
expressed in any forward- looking statements made by the Company,
including, but not limited to, the continuing development of the
Company's sales, marketing and support efforts. DATASOURCE: Zargis
Medical Corp. CONTACT: John Kallassy for Zargis Medical Corp.,
+1-718-567-4358, Web site: http://www.speedus.com/
http://www.zargis.com/ http://www.scr.siemens.com/
Copyright
Speedus (CE) (USOTC:SPDE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Speedus (CE) (USOTC:SPDE)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Speedus Corp (CE) (OTCMarkets): 0 recent articles
More Speedus (MM) News Articles